This is a working overview of Counterion, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-12 and is reviewed periodically as new material appears.
Quality control for NMN materials usually covers identity, assay purity, residual solvents, heavy metals, microbial limits, and moisture content. Certificates of analysis from suppliers may report high-performance liquid chromatography purity, mass spectrometry identity, and elemental impurity testing. Regulatory treatment differs by country: NMN is not an approved drug, and its status as a dietary supplement ingredient or novel food has been debated. Some authorities have restricted sales pending safety and regulatory review, while others allow it under specific categories. Buyers should verify documentation rather than rely on label claims.
Quantifying NMN requires methods that separate it from structurally similar compounds such as nicotinamide, nicotinamide riboside, and NAD+. Common approaches include high-performance liquid chromatography coupled with ultraviolet detection, liquid chromatography with tandem mass spectrometry, capillary electrophoresis, and nuclear magnetic resonance for identity confirmation. Because NMN is polar and often present at low concentrations in biological samples, sample preparation can involve protein precipitation, solid-phase extraction, or derivatization. Isotope-labeled internal standards help correct for matrix effects and recovery losses. Reported concentrations depend heavily on the matrix, extraction protocol, and analytical platform.
Quality control for NMN materials typically includes identity, assay, impurity, and residual solvent tests. Certificates of analysis may report HPLC purity, water content, heavy metals, and microbial limits depending on the intended use. Because commercial NMN is sold as a research chemical or ingredient rather than a standardized drug in many jurisdictions, specifications can vary between suppliers. Independent verification can involve comparing retention time, mass spectrum, and NMR data against a reference standard. Open questions remain about how best to standardize purity claims and biological potency across different production methods.
Analytical identification of NMN usually combines chromatographic separation with mass spectrometric detection. High-performance liquid chromatography coupled to tandem mass spectrometry is common for quantifying NMN in biological matrices and finished materials. Because NMN and related nucleotides share similar masses and retention behavior, method development must resolve potential interferences such as nicotinamide riboside and NAD+. Ultraviolet detection at approximately 260 nm can be used for purity checks when concentrations are sufficient. Nuclear magnetic resonance spectroscopy provides structural confirmation and can distinguish anomeric forms.
Stability testing examines how temperature, humidity, light, and pH affect NMN over time. The compound is generally considered hygroscopic and may degrade faster in aqueous solution than in dry powder form. Phosphate esters can hydrolyze under strongly acidic or alkaline conditions, and elevated temperatures accelerate such reactions. For storage, sealed containers at low temperature with desiccant are typical laboratory practices. Stability-indicating methods should separate NMN from its degradation products, including nicotinamide and nicotinamide riboside, so that purity loss can be tracked accurately.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | −20 °C or below | Desiccated; amber container |
| Water solubility | Soluble | Polar; solution stability varies |
| Appearance | White to off-white powder | May be hygroscopic |
| Common analytical method | LC-MS/MS | Isotope-labeled internal standard often used |
| Common synonyms | NMN; β-nicotinamide mononucleotide | β form is commonly studied |
Quality control for NMN materials typically includes identity, assay, purity, and impurity profiling. Tests may cover residual solvents, heavy metals, microbial limits, and water content, depending on the intended use and local rules. Impurity profiles can include related substances such as nicotinamide, nicotinamide riboside, and NAD+, which may form during synthesis or storage. Because commercial NMN can be offered as different salts or hydrate forms, a certificate of analysis should state the form and the analytical methods used. Independent verification is relevant because supplement markets vary in testing requirements and enforcement.
Laboratory identification of NMN usually relies on chromatographic separation coupled with ultraviolet or mass spectrometric detection. High-performance liquid chromatography with UV absorbance can quantify the compound against a reference standard, while liquid chromatography-tandem mass spectrometry offers lower detection limits and better specificity in complex matrices. Nuclear magnetic resonance spectroscopy can confirm structural identity and isomeric form. Ion chromatography or capillary electrophoresis may be used to identify counterions such as sodium. Method validation includes accuracy, precision, linearity, and limits of detection.
Stability testing examines how temperature, humidity, light, and pH affect NMN over time. The compound is generally stored cold, often at minus twenty degrees Celsius or lower, in a desiccated container protected from light. Aqueous solutions tend to be less stable than dry powder because hydrolysis and dephosphorylation can occur, potentially forming nicotinamide riboside or other degradation products. Stress studies may expose samples to heat, acid, base, oxidation, and strong light to identify likely degradation pathways. Results from such studies help define shelf life and handling recommendations, though exact stability depends on formulation and packaging.
Quality control for NMN materials typically includes appearance, assay, impurity profile, residual solvents, heavy metals, and microbial limits. A certificate of analysis summarizes specified tests, but the underlying methods and laboratory accreditation matter. Regulatory treatment varies by country; NMN is sold as a dietary supplement in some markets, while other jurisdictions restrict its use in foods or classify it differently. Independent verification can reduce risks of mislabeling or substitution. Questions remain about how product purity, storage history, and formulation affect delivered dose in humans.
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
Identity and purity of NMN are commonly assessed by liquid chromatography with ultraviolet detection or mass spectrometry. High-performance liquid chromatography can separate related impurities such as nicotinamide, nicotinamide riboside, and NAD+ depending on the method. Mass spectrometry provides molecular mass confirmation, while nuclear magnetic resonance spectroscopy helps establish structure and anomeric form. Quantitative assays often use calibration curves and, in biological samples, stable isotope-labeled internal standards. Method validation addresses specificity, linearity, accuracy, precision, and limits of detection.
Regulatory treatment of NMN differs by country and has changed over time. In the United States, the Food and Drug Administration has stated that NMN is excluded from the definition of a dietary supplement because it was investigated as a drug before being marketed as a supplement; enforcement and legal interpretation continue to evolve. In the European Union, NMN may require authorization as a novel food before sale. In Japan, NMN has been marketed in some food products, while it is not approved as a therapeutic drug in major markets. These categories affect labeling, permitted claims, and quality oversight.
Solid NMN is generally handled as a moisture-sensitive and light-sensitive material. Suppliers commonly recommend storage at minus 20 degrees Celsius in a sealed, desiccated container, protected from light. Aqueous solutions are less stable than the solid and may degrade faster at elevated temperatures or extreme pH values. Because NMN contains a phosphate ester and a glycosidic bond, hydrolysis and other degradation pathways are plausible under unfavorable conditions. Stability data from independent laboratories remain limited, so handling recommendations often reflect supplier practice rather than published consensus.
Analytical measurement of NMN typically uses high-performance liquid chromatography with ultraviolet detection, often at a wavelength near 260 nanometers. Liquid chromatography coupled with tandem mass spectrometry provides greater sensitivity and specificity, especially for biological samples. Nuclear magnetic resonance spectroscopy can confirm structure and detect certain impurities. Purity values reported by suppliers depend on the analytical method, calibration standards, and whether related compounds such as nicotinamide or NAD+ are included in the calculation. Independent verification is useful because supplement labels may not fully describe the tested material.
=== By honey bees === Honey is produced by bees who have collected nectar or honeydew. Bees value honey for its sugars, which they consume to support general metabolic activity, especially that of their flight muscles during foraging, and as a food for their larvae. To this end bees stockpile honey to provide for themselves during ordinary foraging as well as during lean periods, as in overwintering. During foraging bees use part of the nectar they collect to power their flight muscles. The majority of nectar collected is not used to directly nourish the insects but is instead destined for regurgitation, enzymatic digestion, and finally long-term storage as honey. During cold weather or when other food sources are scarce, adult and larval bees consume stored honey, which is many times more energy-dense as the nectar from which it is made. After leaving the hive, a foraging bee collects sugar-rich nectar or honeydew. Nectar from the flower generally has a water content of 70 to 80% and is much less viscous than finished honey, which usually has a water content around 18%. The water content of honeydew from aphids and other true bugs is generally very close to the sap on which those insects feed and is usually somewhat more dilute than nectar. One source describes the water content of honeydew as around 89%. Whether it is feeding on nectar or honeydew, the bee sucks these runny fluids through its proboscis, which delivers the liquid to the bee's honey stomach or "honey crop".
== Ingredients == The sauce is made primarily of dried chili peppers, chili powder, broad bean paste, Sichuan peppercorn, clove, garlic, star anise, black cardamom, fennel, ginger, cinnamon, salt and sugar. These ingredients are simmered with beef tallow and vegetable oil for many hours, and packed into a jar. Other herbs and spices, such as sand ginger, Angelica dahurica and poppy seeds, can be added to create a unique flavor profile. Traditionally, a restaurant hired a chef specializing in making this sauce; the recipes were kept secret to the chef himself. Today, prepared mala sauce can easily be found in supermarkets, and chain restaurants often produce their own sauce on a large scale, while many others still blend their own. Like curry, there is a constant debate about the 'best' recipe and numerous variations are available on the market.
=== No development reported === 4-Chlorokynurenine (4-CL-KYN; 7-CL-KYNA; AV-101) – ionotropic glutamate NMDA receptor antagonist and 3-hydroxyanthranilate oxidase inhibitor [146] α-Synuclein picobody (a-syn-pico) – positron-emission tomography (PET) enhancer – diagnosis [147] A-86929 – dopamine D1 receptor agonist [148] AB-4166 – microbiome modulator [149] ACI-12589 – positron-emission tomography (PET) enhancer – diagnosis [150] Affitope-PD03 (PD03; PD03A) – α-synuclein inhibitor and immunostimulant [151] ANPD-002 (ANPD002) – dopaminergic cell replacement [152] AP-472 – metabotropic glutamate mGlu4 receptor positive allosteric modulator [153] Aplindore (DAB-452; palindore; SLS-006; WAY-DAB 452) – dopamine D2 receptor agonist [154] Armesocarb (MLR-1019) – atypical dopamine reuptake inhibitor (DRI) [155] Atuzaginstat (COR-388) – peptide hydrolase inhibitor [156] ATV:aSyn (ATV:α-synuclein; ATV:αSyn) – α-synuclein inhibitor [157] Autologous adipose derived mesenchymal stem cells - Hope Biosciences – cell replacement [158] AZ-001 – undefined mechanism of action [159] Beperminogene perplasmid (AMG-0001; Collategene; hepatocyte growth factor gene therapy) – gene transference and hepatocyte growth factor (HGF) expression stimulant [160] BTRX-246040 (LY-2940094) – nociceptin receptor (NOP) antagonist [161] Cannabidiol/tetrahydrocannabinol (CBD/THC; CanChew; MedChew; THC/CBD) – cannabinoid CB1 and CB2 receptor agonist and other actions [162] Carbidopa/levodopa (WD-1603) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [163] Carbidopa/levodopa oral solution (EXN-32) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [164] Ciforadenant (CPI-444, V-81444) – adenosine A2A receptor antagonist CM-4612 (CM-ADHD; CM-AT; CM-PK) – enzyme replacement and modulator [165] Crisdesalazine (AAD-2004) – microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor [166] CTx-GBA1 – gene transference [167] Cu(II)ATSM (copper(II)-ATSM; Cu-ATSM) – neuron modulator [168] Debamestrocel (autologous bone marrow derived mesenchymal stem cell therapy; NurOwn) – dopaminergic cell replacement [169] DNL-201 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [170] Dopamine intranasal – non-selective dopamine receptor agonist [171] DX-0308 (DX-308) – retinoic acid metabolism modulator [172] Emrusolmin (anle-138b; TEV-56286) – α-synuclein inhibitor and protein aggregation inhibitor [173] ESB-1609 – sphingosine-1-phosphate (S1P) receptor agonist [174] ESB-5070 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [175] F-14413 – α2-adrenergic receptor inverse agonist [176] FB-101 (1ST-102) – Bcr-Abl tyrosine kinase inhibitor [177] Fibroblast growth factor 1 (FGF-1) – fibroblast growth factor stimulant and angiogenesis-inducing agent [178] GO-101 – gene transference [179] GT-02329 – β-glucocerebrosidase (GCase) activator and/or chaperone [180] ISC-hpNSC (human parthenogenetic neural stem cells) – dopaminergic cell replacement [181] Itanapraced (CHF-5074; CSP-1103) – γ-secretase modulator and non-steroidal anti-inflammatory drug (NSAID) derivative lacking cyclooxygenase (COX) inhibition [182] Levodopa deuterated (deuterium-containing levodopa; SD-1077) – dopamine precursor and indirect non-selective dopamine receptor agonist [183] Liatermin (BVF-014; GDNF; glial-derived neutrotrophic factor; r-metHuGDNF) – neuron stimulant [184] Lu-AE-04621 (Lu-AE04621) – dopamine receptor agonist (prodrug of Lu-AA40326) [185] Masupirdine (SUVN-502; SUVN502) – serotonin 5-HT6 receptor antagonist [186] Mesocarb (MLR-1017) – atypical dopamine reuptake inhibitor (DRI) [187] MTK-458 – protein-serine-threonine kinase stimulant [188] NPT-200-11 (NPT200-11; UCB-1332) – α-synuclein inhibitor [189] NPT-520-34 (NPT520-34) – 1-phosphatidylinositol 3 kinase modulator and other actions [190] ODM-104 – catechol O-methyltransferase (COMT) inhibitor [191] OP-101 (dendrimer N-acetylcysteine) – various actions [192] OP-501 – catechol O-methyltransferase (COMT) inhibitor [193] Ordopidine (ACR-325) – low-affinity dopamine D2 receptor antagonist and dopaminergic stabilizer [194] PD-04 (a-Syn-PD-04; Affitope PD-04; PD04) – peptide vaccine against α-synuclein [195] Rasagiline – monoamine oxidase B (MAO-B) inhibitor [196] Rasagiline transdermal patch (TPU-002RA) – monoamine oxidase B (MAO-B) inhibitor [197] Research programme: adenosine A2A/A1 selective antagonists - Domain Therapeutics/CleveXel Pharma (CVXL-0069; DT-1133; DT0926; FP-0692; FP-1133) – adenosine A1 receptor antagonists and adenosine A2A receptor antagonists [198] Research programme: catalytic antioxidants - Aeolus Pharmaceuticals (AEOL-10113; AEOL-11207) – antioxidants [199] Research programme: central nervous system therapeutics - Delpor – undefined mechanism of action [200] Research programme: cGAS/STING antagonists - IFM Due – nucleotidyltransferase inhibitors [201] Research programme: COMT inhibitors - Avalo Therapeutics (AVTX-406; CERC-425; CERC-406) – catechol O-methyltransferase (COMT) inhibitors [202] Research programme: dopamine D1 receptor agonists - Takeda – dopamine D1 receptor agonists [203] Research programme: exosome therapeutics - ArunA Biomedical – undefined mechanism of action [204] Research programme: GPCR modulators - Nxera Pharma – various actions [205] Research programme: KEAP1 inhibitors - Keapstone Therapeutics – Kelch-like ECH-associated protein 1 (KEAP1) inhibitors [206] Research programme: long-acting neuropsychiatric therapeutics - Teva (NP-201; NP-202; risperidone/ropinirole implants) – various actions [207] Research programme: LRRK2 inhibitor - GlaxoSmithKline – leucine-rich repeat kinase 2 (LRRK2) inhibitors [208] Research programme: LRRK2 inhibitors - Novartis – leucine-rich repeat kinase 2 (LRRK2) inhibitors [209] Research programme: neurodegenerative disorder gene therapies - Denali Therapeutics (AAV-LF2; CNS-directed AAV-based gene therapies) – gene transference [210] Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience (AD-0802; AD-1502; AD-2203; AE-1501; BAN-2203; BAN-2502; BAN2401 back-up) – various actions [211] Research programme: neurodegenerative disorder therapeutics - Celgene Corporation/Evotec (BMSxxx) – cell replacements [212] Research programme: neurodegenerative disease therapeutics - ProteoTech (DP-68; DP-74; PD-61-W3; PeptiClere; PTI-19; PTI-51; PTI-51-CH3; Synuclere; TauPro) – various actions [213] Research programme: neurological disorders therapeutics - Gloriana therapeutics (ECB-PD; ECT-PD; Meteorin; Ns-G34; NsG-0301; NsG-33) – glial cell line-derived neurotrophic factor modulators [214] Research programme: Parkinson's disease therapeutics - Alectos Therapeutics – glucocerebrosidase 2 (GBA2) protein inhibitor [215] Research programme: Parkinson's disease therapies - Zymes (co-Q10; coenzyme Q10; ubidecarenone) – antioxidants [216] Research programme: Parkinson's disease therapy - AbbVie – dopamine D2 and D3 receptor agonists [217] Research programme: positive allosteric modulators - Proximagen – various actions [218] Research programme: protective autoimmunity enhancer - Proneuron Biotechnologies (PN-277) – immunomodulators [219] Research programme: protein phosphatase 2A modulators - Signum Biosciences (SIG-1012; SIG-1106) – protein phosphatase 2A (PP2A) modulator [220] Research programme: small molecule therapeutics - Amathus Therapeutics – mitochondrial protein stimulants [221] Research programme: small molecule therapeutics - Aranda Pharma/Tarrex Biopharma (ADA-308; ADA-409; Backup; MDA-308; MDA-409) – androgen receptor antagonists [222] Research programme: transmembrane protein 175 agonists - AbbVie/Caraway Therapeutics – TMEM175 stimulants [223] Rotigotine controlled release (SER-214) – non-selective dopamine receptor agonist and other actions [224] S-32504 – dopamine D2 and D3 receptor agonist [225] SAGE-324 (BIIB-124) – GABAA receptor positive allosteric modulator and neurosteroid [226] Saracatinib (AZD-0530) – Src-family kinase inhibitor [227] Selegiline transdermal (Emsam) – monoamine oxidase B (MAO-B) inhibitor and other actions [228] Seridopidine (ACR343; ACR-343) – dopamine receptor modulator and so-called "dopaminergic stabilizer" [229] SLS-004 (LV-dCas9-DNMT3A) – gene therapy and α-synuclein expression inhibitor [230] Sonlicromanol (KH-176) – prostaglandin-E synthase inhibitor and reactive oxygen species modulator [231] SPN-803 (SPN803) – undefined mechanism of action [232] STEL-101 (AMA-101; STL-101) – undefined mechanism of action [233] UB-312 – immunostimulant [234] YKP-10461 (SKL-PD; YKP10461) – monoamine oxidase B (MAO-B) inhibitor [235] YTX-7739 – stearoyl-CoA desaturase inhibitor [236] Xenon (NBTX-001) – ionotropic glutamate NMDA receptor antagonist [237]
== Toxicity == Carbonyl sulfide has the "rotten egg" odor characteristic of sulfides, although some sources suggest that the associated odor is due to impurities, and not present in the pure compound. The detectability threshold is estimated at 135μg/m
After the reforms ended in 1909, the Indian Army was organised along British lines, although it was always behind in terms of equipment. An Indian Army division consisted of three brigades each of four battalions. Three of these battalions were of the Indian Army, and one British. The Indian battalions were often segregated, with companies of different tribes, castes or religions. One and a half million volunteers came forward from the estimated population of 315 million in the Indian subcontinent. Regimental battalions were not permanently allocated to particular divisions or brigades, but instead spent some years in one formation, and were then posted to another elsewhere. This rotating arrangement was intended both to provide all units with experience of active service on the Frontier, and to prevent them becoming 'localised' in static regimental stations. In contrast, the divisional locations remained constant.
Sources: en.wikipedia.org
=== Transport businesses === London North Eastern Railway, Britain (reporting mark: GR) Aurigny Air Services, Guernsey (IATA designator: GR) Gemini Air Cargo, Virginia, US (defunct IATA designator: GR) Goodrich Corporation, an American tire and aerospace manufacturer Toyota Gazoo Racing, a motorsports division
=== Pharmacodynamics === Cocaine acts as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). Cocaine increases levels of serotonin, norepinephrine, and dopamine in the synaptic cleft, leading to heightened post-synaptic activation, with dopamine contributing to euphoria and arousal, and the other monoamines enhancing additional effects. The pharmacodynamics of cocaine involve the complex relationships of neurotransmitters (inhibiting monoamine uptake in rats with ratios of about: serotonin:dopamine = 2:3, serotonin:norepinephrine = 2:5). The most extensively studied effect of cocaine on the central nervous system is the blockade of the dopamine transporter protein. Dopamine neurotransmitter released during neural signaling is normally recycled via the transporter; i.e., the transporter binds the transmitter and pumps it out of the synaptic cleft back into the presynaptic neuron, where it is taken up into storage vesicles. Cocaine binds tightly at the dopamine transporter forming a complex that blocks the transporter's function. The dopamine transporter can no longer perform its reuptake function, and thus dopamine accumulates in the synaptic cleft. The increased concentration of dopamine in the synapse activates post-synaptic dopamine receptors, which makes the drug rewarding and promotes the compulsive use of cocaine. Cocaine affects certain serotonin (5-HT) receptors; in particular, it has been shown to antagonize the 5-HT3 receptor, which is a ligand-gated ion channel.
Liquid Scintillation Counting, University of Wisconsin–Milwaukee Radiation Safety Program Principles and Applications of Liquid Scintillation Counting, National Diagnostics K. Regan, "Cerenkov counting technique for beta particles: advantages and limitations". J. Chem. Educ., August 1983, 60 (8), 682–684. doi:10.1021/ed060p682
Nadolol is a non-selective beta blocker; that is, it non-selectively blocks both beta-1 and beta-2 receptors. It has a preference for beta-1 receptors, which are predominantly located in the heart, thereby inhibiting the effects of catecholamines and causing a decrease in heart rate and blood pressure. Its inhibition of beta-2 receptors, which are mainly located in the bronchial smooth muscle of the airways, leads to airway constriction similar to that seen in asthma. Inhibition of beta-1 receptors in the juxtaglomerular apparatus of the kidney inhibits the renin–angiotensin system, causing a decrease in vasoconstriction and a decrease in water retention. Nadolol's inhibition of beta-1 receptors in the heart and kidney leads to its effects on lowering blood pressure. The drug impairs AV node conduction and decreases sinus rate. Nadolol may also increase plasma triglycerides and decrease HDL-cholesterol levels.
=== Product recalls === In May 2006, a sale of the seats from Arsenal F.C.'s old stadium, Highbury in London, England was cancelled when the seats were discovered to contain trace amounts of cadmium. Reports of high levels of cadmium use in children's jewelry in 2010 led to a US Consumer Product Safety Commission investigation. The U.S. CPSC issued specific recall notices for cadmium content in jewelry sold by Claire's and Wal-Mart stores. In June 2010, McDonald's voluntarily recalled more than 12 million promotional Shrek Forever After 3D Collectible Drinking Glasses because of the cadmium levels in paint pigments on the glassware. The glasses were manufactured by Arc International, of Millville, New Jersey, USA.
Sources: en.wikipedia.org
Liquid chromatography with tandem mass spectrometry is common because it can quantify low levels of NMN in complex samples. High-performance liquid chromatography with ultraviolet detection is used for simpler purity checks. Nuclear magnetic resonance can confirm identity and detect some impurities.
Solid NMN is typically kept desiccated at −20 °C or below and protected from light. Sealed containers reduce moisture exposure, which can promote degradation. Aqueous solutions are generally less stable and are often prepared fresh.
Important checks include identity confirmation, purity assay, moisture, heavy metals, residual solvents, and microbial contamination. A certificate of analysis should list the methods used and the specification limits. Independent testing can help verify supplier claims.
Common methods include HPLC with ultraviolet detection and LC-MS/MS. These techniques separate NMN from related nucleotides and quantify it by retention time and mass-to-charge ratio.